With diversified management experience in the life science industry and over 100 years of collective experience, our team is well equipped to change the shape of medical research.

Keith Murphy, Chairman and Chief Executive Officer

Mr. Murphy has 20 years of experience in biotechnology, including serving in Product Strategy and Director of Process Development roles at Amgen. He is a co-founder of Organovo and has been responsible for all company operations since 2007. His ten years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. At Amgen, he also worked to develop several other novel formulation and device products. Prior to Amgen, he played a central role at Alkermes, Inc. on the development team for their first approved product, Nutropin (hGH) Depot. He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management. Mr. Murphy serves as Vice Chairman of the Alliance for Regenerative Medicine, comprised of over 120 member companies, patient advocacy foundations, venture capital firms, and academic research institutes focused on the advancement of regenerative medicine through engagement with government leaders and cooperative efforts.

Barry Michaels, Corporate Secretary and Chief Financial Officer

Mr. Michaels has more than 30 years of financial and general management experience in the medical device and biotechnology industries. He has served as CFO of three private and three publicly traded companies: Cardima, Inc. (NASDAQ), Lipid Sciences, Inc. (NASDAQ), IntraTherapeutics, Inc., VIA Medical, Inc., Webster Laboratories (now a division of J&J/Cordis known as Biosense-Webster), and ICN Biomedicals, Inc. (AMEX). He has also served as an independent consultant to medical device and biotechnology companies since 1997. Mr. Michaels began his medical industry career in 1979 with Baxter Healthcare, where he held various management and executive positions in accounting and finance through 1988, most recently as Vice President and Controller of the Parenteral Products Group, before continuing his career as Vice President and Corporate Controller of Medtronic, Inc. Mr. Michaels holds an M.B.A. in finance from San Diego State University and is a graduate of the Executive Program at the University of California, Los Angeles.

Sharon Collins Presnell, Ph.D., Chief Technology Officer and Executive Vice President of Research & Development

Dr. Presnell has more than 18 years of experience in the leadership of product-focused R&D. As an assistant professor at the University of North Carolina at Chapel Hill, Dr. Presnell’s research in liver and prostate biology and carcinogenesis produced cell- and tissue-based technologies that were outlicensed for industrial applications. She joined Becton Dickinson (BD) in 2001 and played a key role in the early discovery and development of BD’s Discovery Platform and FACSTM CAP tools for the optimization of in vitro culture environments and flow cytometry-based characterization of cells. In her role at BD, she grew and led a large multi-disciplinary team to establish feasibility for the Discovery Platform and FACS CAP in multiple therapeutic areas, including diabetes, and stewarded both technologies through revenue-generating commercial partnerships. Dr. Presnell joined Tengion, Inc. in 2007 as the Vice President of Regenerative Medicine Research, and was responsible for the discovery and early development of Tengion’s Neo-Kidney Augment™ technology, which MedTronic secured first rights to purchase in a 2011 deal. Dr. Presnell holds a Ph.D. in pathology from the Medical College of Virginia.

Eric Michael David, M.D., J.D., Chief Strategy Officer

Dr. David has more than 15 years of experience in biomedical research and product development. He played a critical role in the commercial translation of 3D bioprinting as a founder and early director of Organovo, Inc. Dr. David was most recently associate partner at the consultancy McKinsey & Company, where he served private equity, pharmaceutical, biotech, diagnostic, and medical device clients to support pipeline and R&D strategy, as well as market entry strategy. Prior to his time at McKinsey, Dr. David served as a freelance consultant to the Department of Health and Human Services in the use of genomic technologies for early detection of pathogens for public health preparedness. He completed his residency in Internal Medicine at New York Presbyterian Hospital, where he served as Assistant Chief Resident and received the Dick Bowman Award for scientific endeavor and dedication to patient care. He was also Assistant Professor at The Rogosin Institute, adjunct faculty at The Rockefeller University, and a lecturer in Medicine at Weil Cornell Medical College. He received his M.D. from Columbia University College of Physicians and Surgeons, his J.D. from Columbia University School of Law, and a B.A. in Physics and Fine Arts from Amherst College. He is board certified in Internal Medicine and admitted to the Bar in New York State.

Michael Renard, Executive Vice President of Commercial Operations

Mr. Renard has more than 29 years of recognized, revenue-generating experience in commercial operation, business development and sales and marketing for the life science industry. With Beckman Coulter, he held various positions in program management, business operations and business development. He most recently was the vice president of marketing for North America commercial operations where he was responsible for achieving $2 billion in revenue across 11 major product lines. Before Beckman Coulter, he was vice president and general manager in a development-stage incubator division of Sanofi, Inc. and director of corporate accounts at Kallestad Diagnostics. Mr. Renard holds an M.B.A from Rockhurst University and a B.A. in Biology and Chemistry from St. Olaf College.